After that, five tumor antigens (ALOX15B, HS3ST2, PIGR, ZMYND15, and LIMK1) were identified to be candidates for the mRNA-based vaccine development, all of which were correlated with survival time of PRCC patients and the degree of APC infiltration. The gene discussed is HS3ST2; the disease is neoplasm.